Atara Biotherapeutics’ Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Only Approved Therapy for EU Patients with Rare and Potentially Deadly Cancer Facing Median Survival of Only a Few Months Represents First Approval of an Allogeneic T-Cell Immunotherapy Globally Pierre Fabre to Lead Commercialization and Distribution Activities in Europe THOUSAND OAKS,...

Click to view original post